About
This medication combines linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, providing a complementary and robust strategy for managing type 2 diabetes mellitus. Linagliptin functions by increasing active incretin hormone levels, which in turn enhance glucose-dependent insulin secretion and suppress glucagon release. Empagliflozin acts independently of insulin by reducing renal glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and a subsequent reduction in blood glucose levels. This dual mechanism not only provides potent glycemic control but also offers additional significant benefits, including potential weight reduction and established cardiovascular and renal protective effects. These broader benefits make this combination a valuable therapeutic option for patients requiring comprehensive management beyond just blood sugar lowering, particularly as an adjunct to diet and exercise.
Uses
- Management of type 2 diabetes mellitus.
- Improvement of glycemic control.
- Reduction of cardiovascular death risk in patients with established cardiovascular disease.
- Reduction of risk of hospitalization for heart failure.
Directions For Use
Take orally once daily in the morning, with or without food, as directed by your healthcare provider.
Benefits
- Significant HbA1c reduction.
- Weight loss potential.
- Reduced risk of cardiovascular death.
- Reduced risk of hospitalization for heart failure.
- Renal protective effects.
- Low risk of hypoglycemia when used alone.
Side Effects
- Urinary tract infections (UTIs)
- Genital mycotic infections (e.g., yeast infections)
- Increased urination
- Thirst
- Hypotension (low blood pressure)
- Ketoacidosis (rare, but serious)
- Kidney problems (acute kidney injury)
- Nasopharyngitis
- Joint pain
- Hypoglycemia (when combined with sulfonylureas or insulin)
- Back pain
- Flu-like symptoms
Safety Measures
- Alcohol - Excessive alcohol intake may increase the risk of ketoacidosis and affect blood glucose levels; use in moderation.
- Pregnancy - Not recommended during the second and third trimesters due to potential adverse effects on fetal kidney development.
- Breastfeeding - Not recommended due to potential for serious adverse reactions in breastfed infants; consider alternatives.
- Liver - Generally safe for use in patients with mild to moderate hepatic impairment; severe impairment requires caution.
- Kidney - Not recommended for initiation in patients with eGFR <30 mL/min/1.73m²; efficacy is reduced with declining renal function.
- Lung - No specific contraindications or dose adjustments related to lung conditions are typically noted.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!